Angioplasty Balloons Market By Product Type (Plain Old Balloon Angioplasty, Drug-Eluting Balloons, Cutting Balloons, Scoring Balloons, Specialty Balloons, Other), By Material Type (Semi-Compliant Balloons, Non-Compliant Balloons), By Balloon Catheter Type (Over-the-Wire Balloon Catheter, Rapid Exchange Balloon Catheter, Fixed Wire Balloon Catheter), By Application (Coronary Angioplasty, Peripheral Angioplasty, Neurovascular Angioplasty, Renal Angioplasty), and By End-user (Hospital, Ambulatory Surgical Centers, Specialty Cardiac Center), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Angioplasty Balloons market accounted for USD 2.84 Billion in 2024 and is expected to reach USD 4.42 Billion by 2035, growing at a CAGR of around 4.1% between 2025 and 2035. The Angioplasty Balloons Market is the company operating with minimally invasive procedures with healthcare medical equipment to treat narrowed or blocked blood vessels. These balloons are the core of angioplasty since they are inserted into an artery or vein and inflated to expand the vessel, thus enabling blood flow.

They are used primarily in the treatment of coronary artery disease and peripheral artery disease. The market includes plain, drug-coated, and cutting balloons. Each of them is designed to meet specific medical needs. Newer materials and coatings improve safety and efficacy while reducing complications. The increasing incidence of cardiovascular diseases and the increasing geriatric population are driving the demand for such devices. It is widely adopted in hospitals and ambulatory surgical centers, where favorable reimbursement policies are in place in many regions.

Report Scope:

Market Dynamics

Increasing awareness of cardiovascular disease prevention and treatment

The Angioplasty Balloons Market is growing due to increasing awareness about cardiovascular disease prevention and treatment. With the constant increase in the number of people suffering from heart disease all over the world, governments, healthcare systems, and consumer protection organizations are investing more in creating awareness of heart health. Advocacy for lifestyle changes, such as proper diet, exercise, and early presentation, has forced people to seek medical attention as soon as they notice symptoms. The demand for angioplasty balloons has increased as a result of increased use of preventative care and less invasive procedures like angioplasty brought about by increased health literacy. Furthermore, the rate of innovation in angioplasty instruments and technology has increased due to practitioners' increased concern about the availability of improved treatments.

Improved access to advanced medical devices in emerging economies

Improved access to advanced medical devices in emerging economies is a significant driver for the Angioplasty Balloons Market. The governments in these regions have invested much in health care infrastructure as cardiovascular diseases become a widespread problem. Measures to reduce the cost of medical devices and reduce the number of bureaucratic approvals to install angioplasty balloons have increased their affordability and accessibility.

According to the WHO, 85% of premature deaths from cardiovascular diseases occur in low- and middle-income countries; therefore, urgent intervention is necessary. Such statistics explain the trend and growing usage of angioplasty balloons among other minimally invasive procedures that take place within the countries concerned.

Lack of trained professionals in some regions to perform advanced angioplasty procedures

One of the major factors that most affects the Angioplasty Balloons Market is the scarcity of skilled personnel in some areas. In many emerging markets, access to qualified cardiologists and other medical specialists who are proficient in the use of new-generation angioplasty tools and procedures, such as drug-coated or cutting balloons, is still limited. This is often due to a lack of training facilities, limited opportunities for obtaining additional education, and the high cost of professional education. For a variety of reasons, technological advancement may not be fully adopted or implemented in healthcare settings, which limits the market's growth in these regions.

As a result, many patients will have to wait a long time for treatment, complications may arise, and substandard clinical results may occur due to the use of traditional or technically less efficient angioplasty balloons. Increasing educational outreach and offering courses and training are some ways to address these issues, but improving healthcare access globally remains a persistent challenge.

Rising Prevalence of Cardiovascular Disease especially in aging populations

Cardiovascular disease (CVD) is increasing rapidly, especially in the aging population, and this is where angioplasty balloons hold the brightest future. Hypertension and atherosclerosis are other diseases that become more common with age and thus call for such complex treatments as angioplasty. Angioplasty is becoming more popular than standard surgery for patients with CVD since it is a noninvasive procedure that only requires a few days in the hospital. Also, people are aging at extremely rapid rates; according to current UN predictions, 22% of the world's population will be 60 years of age or older by 2050. According to the estimate, there will be a greater need for cardiovascular systems, which means that angioplasty balloons will be crucial in effectively treating heart conditions.

Increased international demand for high-quality, cost-effective treatments

The expanding global need for higher-quality treatments at competitive prices is one of the unique opportunities for the Angioplasty Balloons Market. People want to access high and complex levels of care, especially in LMICs, but they are looking for value for money. The destinations and healthcare facilities associated with medical tourism and globalization are using price superiority to lure global clients for angioplasty. Angioplasty balloons at competitive prices are supplied by countries with highly developed health sectors, which are global players, meeting quality needs.

The World Bank has reported that out-of-pocket health expenditure is a large component of total health expenditure within developing countries, and hence the demand for cost-effective yet efficient medicines. This trend makes it possible for angioplasty balloon manufacturers to meet both the local and export markets since quality can be developed hand in hand with the cost aspect.

Industry Experts Opinion

"Medtronic is committed to offering physicians a suite of products to treat patients with PAD. Based on feedback from our clinical community and the need for an 018” guidewire compatible DCB, Medtronic is excited to bring this technology to market in the U.S."

• Geoff Martha, CEO, Medtronic

Segment Analysis

Based on the product type, the Angioplasty Balloons Market is classified into plain old balloon angioplasty (POBA) balloons, drug-coated balloons (DCB), cutting balloons, and scoring balloons. The plain old balloon angioplasty (POBA) balloons are the standard ones that are mainly employed to facilitate the establishment of wider arteries through the mechanical deformation of plaque. This technique is becoming favored over others because it involves the use of a drug-coated balloon, which poses less risk for restenosis, and no repeat procedures are necessarily needed. Electro balloons use a wire or scoring component to focus force, which is more advantageous and safer for some challenging vascular pathology situations. The drug-eluting balloon segment is expected to offer the highest growth rate due to the better results associated with DCBs and increasing usage in coronary as well as peripheral arteries diseases.

Based on the application, The Angioplasty Balloons Market is classified into two major categories, namely coronary angioplasty and peripheral angioplasty. Because blockage of one’s arteries is a common problem all over the world; the treatment of these blockages through coronary angioplasty makes this segment dominant. While peripheral angioplasty deals with the dilation of blockages in arteries that are not inside the heart, including those in the legs, arms, or kidneys, it is steadily on the rise because of the rising rates of PAD. The specific demand for drug-coated balloons is high for both of these designs since they lower the restenosis rates.

Regional Analysis

The North American region is the largest Angioplasty Balloons Market due to various reasons, such as the high incidence of cardiovascular diseases, improved and advanced healthcare facilities & amenities, and the increasing acceptability of minimally invasive surgery procedures. It has the largest stake due to strong research activities, major players in the market, and favorable reimbursement policies. Europe comes second because of the rising aging population, enhanced knowledge about cardiovascular health, and improvement in technology. In the European market, some leaders can be highlighted, such as Germany, the UK, and France.

The Asia-Pacific region is the fastest-growing Angioplasty Balloons Market at a healthy rate due to the increasing frequency of CVDs, increasing population age, and better healthcare facilities. Some of the major developments in this market are displayed by China, India, and Japan because of the increased population of patients and the growing consciousness of conservative surgical procedures. Such factors as the increase in urban area population, changes in lifestyles that have resulted in increased lifestyle diseases, and government efforts to increase access to health facilities have greatly contributed to this growth. Also, there is a growing trend in medical technology investment as well as a surge in activity in medical tourism in countries like India and Thailand, where the cost of healthcare services is relatively low, but quality is not compromised.

Competitive Landscape

The competition in the Angioplasty Balloons Market is expected to remain high, with global and regional players working towards research and development, new product launches, and geographical expansion. Market leaders are transferring advanced technologies and have prospective distribution networks across the globe, and some of them are Boston Scientific Corporation, Medtronic plc, and Abbott Laboratories. B. Braun Melsungen AG, Terumo Corporation, and Cordis are investing in offering a diverse range of angioplasty balloons to fit increasing needs.

Biotronik SE & Co. KG and Cook Medical focus on the production of the latest products through increased investment in research and development aimed at the efficacious delivery of their products. New industry players such as Natec Medical, Hexacath, and Endocor Gbmh are the new entrants that have added competition by offering new cost-efficient products. AngioDynamics, Inc. and Roxwood Medical are implementing several tactics, including joint ventures, acquisitions, and market entry. These are some of the well-known tactics that businesses use.

Angioplasty Balloons Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In July 2024, Teleflex Incorporated received FDA clearance for its Ringer Perfusion Balloon Catheter Type (PBC), the first of its kind for percutaneous transluminal coronary angioplasty (PTCA). This innovative catheter features a helical balloon design that maintains coronary blood flow during balloon inflation, enabling improved myocardial perfusion and facilitating the delivery of additional devices during procedures.
• In March 2024, Boston Scientific Corporation disclosed that it had obtained FDA approval for its AGENT Drug-Coated Balloon (DCB). This device is designed to treat coronary in-stent restenosis (ISR) in individuals suffering from coronary artery disease. ISR occurs when a previously stented artery experiences narrowing or blockage due to the buildup of plaque or scar tissue. This new approval aims to enhance treatment options for patients facing this complication.
• In March 2024, a BIDMC-led trial resulted in the FDA's approval of coronary drug-coated balloons (DCBs), marking a breakthrough in the treatment of coronary artery disease. The trial demonstrated the effectiveness of DCBs in reducing restenosis and improving patient outcomes. This approval paves the way for broader clinical applications of DCBs, offering a promising option for patients undergoing coronary interventions.

Report Coverage:

By Product Type

• Plain Old Balloon Angioplasty (POBA)
• Drug-Eluting Balloons
• Cutting Balloons
• Scoring Balloons
• Specialty Balloons
• Other

By Material Type

• Semi-Compliant Balloons
• Non-Compliant Balloons

By Balloon Catheter Type

• Over-the-Wire (OTW) Balloon Catheter
• Rapid Exchange (RX) Balloon Catheter
• Fixed Wire (FW) Balloon Catheter

By Application

• Coronary Angioplasty
• Peripheral Angioplasty
• Neurovascular Angioplasty
• Renal Angioplasty

By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Cardiac Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Boston Scientific Corporation
• Medtronic plc
• Abbott Laboratories
• B. Braun Melsungen AG
• Terumo Corporation
• Cordis
• Biotronik SE & Co. KG
• Cook Medical
• Endocor GmbH
• Natec Medical
• Hexacath
• AngioDynamics, Inc.
• Koninklijke Philips N.V.
• Acrostak
• Roxwood Medical

Frequently Asked Questions (FAQs)